Rucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]
A pivotal Phase 3 trial called VECTRA-01 has launched to evaluate AZD2265 (²²⁵Ac-PSMA-I&T), an alpha-emitting radioligand therapy targeting PSMA-positive metastatic castration-resistant prostate cancer. The study began in May 2026, enrolling approximately 670 participants across 90 global sites, with recruitment currently active at select locations. The trial’s primary objective is to demonstrate superiority over standard of […]
In the phase 3 CaBRA trial, carboplatin is added to the docetaxel-based chemotherapy backbone used with lifelong ADT (androgen deprivation therapy) and darolutamide, creating a quadruple-intensification therapy for a small but very high-risk subgroup of metastatic castration-sensitive prostate cancer. The trial focuses on tumors with either BRCA alterations or neuroendocrine differentiation, two features that are […]
Results from the PSMAddition trial were published in a phase 3 setting and showed several clear numbers worth noting. The trial compared standard double hormone-based treatment alone (ADT + ARPI) versus the same treatment plus a PSMA-targeted radioligand therapy (Pluvicto), in men with metastatic hormone-sensitive prostate cancer.The biggest headline was a 58% lower risk of […]
Nature reports the results of the HC‑1119‑04 trial, a randomized, multicenter, double‑blind, placebo‑controlled phase 3 study of deutenzalutamide (HC‑1119) in metastatic castration‑resistant prostate cancer (mCRPC) after treatment with abiraterone and docetaxel. The trial was conducted in China and enrolled 417 patients, with 276 randomized to deutenzalutamide 80 mg once daily and 141 to placebo. All […]
Hormone therapy has been a cornerstone for treating advanced prostate cancer, starving tumors of the male hormones they crave to grow. But it often brings harsh side effects like crushing fatigue, hot flashes, high blood pressure, and loss of muscle mass that make daily life a struggle for many men. Now, a major new UK […]
The phase 3 trial CAPItello-281, has delivered compelling evidence that capivasertib combined with abiraterone could transform treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), a subtype affecting a substantial portion of advanced cases. In this double-blind study, 1012 patients with PTEN deficiency (defined rigorously as 90% or more viable malignant cells showing no cytoplasmic staining […]
Radium-223 plus enzalutamide significantly boosts survival for men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases, according to final results from the Phase 3 PEACE-3 trial presented at ASCO GU 2026. In this study of 446 patients with at least two bone metastases who were asymptomatic or only mildly symptomatic, adding six infusions of […]
Saruparib (AZD5305), a next-generation PARP1-selective inhibitor, represents a promising evolution in prostate cancer therapy, particularly for metastatic castration-sensitive disease (mCSPC), through the ongoing phase III EvoPAR-PR01 trial. Unlike first-generation PARP inhibitors (PARPi) such as olaparib that target both PARP1 and PARP2, saruparib specifically inhibits and traps PARP1 on DNA damage sites, sparing PARP2 to potentially […]
BNT324 (DB-1311) is rapidly emerging as one of the most promising new agents in metastatic castration-resistant prostate cancer (mCRPC), with a data package that is unusually strong for a first-in-class B7-H3–targeting antibody–drug conjugate and now compelling enough to justify a head‑to‑head Phase 3 trial against docetaxel. The reason it has attracted so much attention is […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy